Welcome to today's show. I'm Kate Woda, director of the Immunooncology three sixty Summit, or most commonly known as IO three sixty. The IO three sixty Summit will take place February tenth through twelfth in Boston, Massachusetts, and I'm excited to give you a sneak peek into what's ahead and what we'll be diving into this year and why this meeting is so incredibly important in the oncology space. We
have a lot to cover this year. The science is moving fast, the global landscape is evolving, and a great deal of innovation is coming out of China right now. All of this is shaping the direction of amminooncology and IO three sixty is where we come together to unpack it all. So what role does IO three sixty play
in bringing the key stakeholders together. IO three sixty was really designed to be the forum that unites every part of the cancer immunotherapy ecosystem, from academia and biotech to pharma investors and regulators, to share insights, address challenges, and accelerate the next generation of immunooncology treatments. It's about collaboration, connecting the science with the business to drive meaningful impact across cancer types and to make the next wave of
immunooncology a reality. The summit spans three days and it's built on several key pillars pre clinical and discovery, translational, clinical development, and business aspects. We also dig into the spaces in between biomarkers, ADCs, imaging, cell therapy, autoimmune disease combination strategies, and deal making, to name a few. It's a packed agenda offering a balance look at both the
science and the strategy driving the field forward. This year, we're especially excited about sessions on novel biologics including cytokines by specifics and ADCs, as well as in vivo carti and the growing role of AI in advancing amminotherapy. The program is intentionally moving beyond PD one I inhibitors and beyond just T cell focus, because that's what it takes to move the field forward and improve outcomes for people
living with cancer. And we've built in plenty of flexibility so attendees can tailor their experience to focus on what matters most to them. Now, let's talk about our incredible lineup of keynote speakers. Each of whom is helping define the next era of immunooncology. We're delighted to have doctor Jed Wallchok of Wheal Cornell Medicine on Checkpoints and Beyond
the next era of IO. Doctor Miriam Morod of Mount Sinai School of Medicine on targeting mylloid cells, Doctor Andrea Cursik of Memorial Sloan Kettering Cancer Center on dostor Lamab's next chapter, Doctor Ira Mellman of Parker Institute for Cancer Ammunotherapy on redefining cancer amunotherapy, and doctor Andrew Baum a Pfizer on strategic innovations and industry trends. All of these
experts share one and thread. They're bringing insights that connect the science, the business and the future challenges shaping the growth of IO. And of course we'll once again host the annual IO three sixty Debate, one of the most anticipated sessions every year. It's an entertaining and thought provoking way to explore serious topics in oncology, full of insight, honesty, and yes, a little humor. It always gets people thinking differently.
Beyond the sessions, IO three sixty is also about connection. You'll find networking breaks, luncheons, event receptions, and a dedicating partnering tool that helps facilitate one on one meetings a great way to discuss collaborations and partnerships. Our exhibit hall is curated specifically for the immunooncology, cell and gene therapy communities. It's not overwhelming like a massive trade show. It's the perfect balance of learning, connection and exploring. And don't miss
the poster sessions, which are always a highlight. They create another layer of learning and engagement for attendees. For more information on the program, full agenda, and ways to participate, visit iothree sixty summit dot com. Once again, the IO three sixty Summit takes place February ten through twelfth in Boston, Massachusetts. We hope to see you there. Thanks for tuning in and stay tuned for more updates as we get closer to the event.